Navigation Links
Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
Date:6/4/2008

line that includes its lead compound, AR- 67, which is currently being investigated in a Phase I clinical study, as well as AR-12 and AR-42, two novel, preclinical, cancer therapies.

AR-67 is a novel, third-generation camptothecin analogue that has demonstrated high potency in preclinical studies and improved pharmacokinetic properties, as demonstrated by the increased stability of the active lactone form of AR-67 in blood samples. Preclinical studies and preliminary Phase I data confirm that AR-67 maintains a greater proportion of drug in the active lactone form as compared with approved second-generation products, a characteristic that Arno believes may translate to superior clinical activity. Moreover, the potential for oral administration may increase patient convenience. A Phase I clinical study of AR-67 in patients with advanced solid tumors is currently ongoing. Multiple Phase II studies are planned for initiation in 2008 in a variety of cancers, including glioblastoma multiforme (GBM), a highly aggressive form of brain cancer.

AR-12 is a PDK-1 inhibitor that targets the Akt pathway while also possessing activity in the endoplasmic reticulum (ER) stress and other pathways targeting apoptosis. Preclinical data have demonstrated that AR-12 has activity in a wide range of tumor types and shows promising activity in combination with several widely used anti-cancer agents including Avastin(R), Herceptin(R), Gleevec(R), Tarceva(R) and tamoxifen.

AR-42 is a targeted inhibitor of the Pan-DAC and Akt pathways. In preclinical studies, AR-42 has demonstrated greater potency and a competitive profile in tumors when compared with vorinostat (SAHA), the leading marketed histone deacetylase inhibitor. Arno plans to initiate Phase I studies of AR-42 and AR-12 in early 2009.

Arie Belldegrun, M.D., FACS, Chairman of the Board of Directors of Arno added, "This is an important milestone for our company. Attracting sufficient capital was a key objectiv
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
2. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
9. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
10. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
11. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... and PITTSBURGH , July 27, 2015 /PRNewswire/ ... will hold its extraordinary general meeting of shareholders in connection ... PRGO ; TASE) at the Okura Hotel Amsterdam on Friday, ... Among other agenda items at the extraordinary ... approval, under article 2:107a of the Dutch Civil Code, of ...
(Date:7/27/2015)... , July 20, 2015 ... announced the addition of the "Cardiometabolic Drug ... Afrezza,s discounted pricing is in line with ... critical to the product,s commercial appeal. However, contraindications, ... Afrezza from gaining a sizeable share of the ...
(Date:7/27/2015)...  Linear accelerators used to treat patients with ... adequate space for the equipment itself, but also ... the size and complexity of the technology, full ... of a new vault constitutes a formidable undertaking ... patient treatment: with potential negative long-term effects for ...
Breaking Medicine Technology:Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 2Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 3Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 4Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 5Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 6Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 7Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 8Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 9Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 10Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3Accelerating the Design Process for Cancer Treatment Centers 2Accelerating the Design Process for Cancer Treatment Centers 3
... 23, 2011 PharmacoFore, Inc., a privately held ... announced positive results from a Phase I human ... Molecular Delivery™ (Bio-MD™) product candidate, PF329.  Greg Sturmer, ... 2011 BIO Business Forum during the annual BIO ...
... Luminex Corporation (NASDAQ: LMNX ) has ... Most Innovative Company of the Year (for companies with ... Year for the MAGPIX System.  A record number of ... organizations from virtually all company sizes and industries.  In ...
Cached Medicine Technology:PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was 2PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was 3PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was 4Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System 2Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System 3
(Date:7/27/2015)... ... July 28, 2015 , ... ... as the sports medicine provider for the entire school district including Anderson County ... ACHS Athletic Director Rick Sallee, “Student safety and well-being are a top priority ...
(Date:7/27/2015)... ... July 28, 2015 , ... The National Association of Professional ... VIP Woman of the Year Circle. She is recognized with this prestigious distinction for ... boasting more than 700,000 members and over 200 operating Local Chapters. , “I’m pleased ...
(Date:7/27/2015)... ... July 27, 2015 , ... Interactive health education is ... this year Wound Care Advantage beta launched Luvo University, an online ... Customized learning paths allow for clinicians, physicians, hyperbaric technicians and non-clinical staff ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... transformed the science of the little-known and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), ... American Academy of Neurology (AAN). The FSHD care guideline is published today. ...
(Date:7/27/2015)... ... ... Looking to brush up on all the things you should be doing ... enhanced its Dental webpage with new materials, including user-friendly, educational videos, to help members ... to offering our 3.8 million members tools and resources to help them keep a ...
Breaking Medicine News(10 mins):Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 2Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 3Health News:NAPW Inducts Joanne Saniewski, Principal of the Frontier School District's Big Tree Elementary, Into its VIP Woman of the Year Circle 2Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 2Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 3Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2Health News:Thinking about a Dental Check-up? Check out Horizon Blue Cross Blue Shield of New Jersey’s Enhanced Website for a Dental Download of Helpful Information 2
... Leverages Personal Health Care Utilization and Employee Data to ... WHO: Daryl Ashley, senior vice president and general ... Benefits Administration for Workscape, a leading ... Will be a featured presenter in the "Getting Personal -- ...
... and anchor ... depth, ... SN) Endoscopy Division today announced the launch of the,BIORAPTOR 2.3 PK Suture ... is featured at Smith & Nephew Endoscopy,s booth,at the American Academy of ...
... Care,Spending May More Than Double as Hospital Capacity Declines And Baby Boomer ... ... of over 70,million aging baby boomers could overwhelm the U.S. health care ... the,Boom Bust Health Care?," by management consulting firm Tefen USA., A ...
... to Invest in Your Teeth, VOORHEES, N.J., March ... should be similar for 2007. Together with the,government,s economic ... in the pockets of most taxpayers this Spring, it,s ... vacations., But rather than getting away for a ...
... Associate at Kendle ... International, Inc., Joins Catalyst, CORAL GABLES, Fla., March 5 ... the,appointment of Patrick Kenny as Director - Corporate Clinical Compliance.,In ... and GCP compliance of the CROs, clinical contractors and,clinical trial ...
... 1999,OurHealthNetwork.com ( http://www.OurHealthNetwork.com ) has been the,Internet,s leading ... board- certified podiatrists now introduces an exclusive line ... orthotics that not only,provide relief to those who ... their,lifestyles and shoe styles. Now for the first ...
Cached Medicine News:Health News:Upcoming Business Health Agenda 2008 Features Workscape Executive 2Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 2Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 3Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 4Health News:New Study: Aging Baby Boomers Could Overwhelm U.S. Health Care System by 2017, Unless Decisive Action Is Taken 2Health News:New Study: Aging Baby Boomers Could Overwhelm U.S. Health Care System by 2017, Unless Decisive Action Is Taken 3Health News:New Study: Aging Baby Boomers Could Overwhelm U.S. Health Care System by 2017, Unless Decisive Action Is Taken 4Health News:Smile When You Get that Refund 2Health News:Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance 2Health News:Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance 3Health News:Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance 4Health News:Unique Line of Custom-Made Orthotics for Sandals and Clogs Cater to Style-Minded Foot Pain Sufferers 2
Well established test for children but suitable for disabled people, those with learning difficulties or patients who do not share a common language with the examiner....
The FLEXI-CUT Directional Debulking System is Abbott Vascular's latest atherectomy catheter designed to enhance performance and ease-of-use....
This test displays normal protan, deutan and tritan colors, differentiation is stronger in the red/green., ,Significant tritan defects may be detected if used in conjunction with the Ishihara. Th...
The New Vantage Plus. The PLUS gives you: ,P Premium intelligent optics ,L Lighter weight and brighter images ,U Unique wireless patented technology ,S Smaller and more compact size ...
Medicine Products: